Important Prescribing Information
Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib.
Pemigatinib is an oral FGFR inhibitor used in selected cancer treatment settings involving specific molecular abnormalities.
This page provides an educational summary of important prescribing information associated with the established U.S. reference product containing pemigatinib.
It is not a substitute for the complete official prescribing information supplied with the medicine. The regulatory status and product-specific prescribing instructions for Pemitinib must be verified independently.
Active Ingredient
Generic name: Pemigatinib
Product name identified on this website: Pemitinib
Stated strength: 13.5 mg
Drug class: Fibroblast growth factor receptor inhibitor
Molecular targets: FGFR1, FGFR2 and FGFR3
Route of administration: Oral
Therapeutic Indications
Under U.S. reference-product prescribing information, pemigatinib is indicated for the following conditions.
1. Previously Treated FGFR2-Altered Cholangiocarcinoma
Pemigatinib is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an FGFR2 fusion or another qualifying rearrangement detected by an FDA-approved test.
The treatment is intended for patients who meet the specified molecular and clinical eligibility requirements.
2. FGFR1-Rearranged Myeloid/Lymphoid Neoplasms
Pemigatinib is indicated for adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement under U.S. labeling.
The treatment indication, eligibility criteria and dosage must be interpreted according to the applicable regulatory information.
Dosage and Administration
The reference-product prescribing information describes the following schedules.
| Indication | U.S. labeled dosage |
|---|---|
| FGFR2-altered cholangiocarcinoma | 13.5 mg once daily for 14 days, followed by 7 days off |
| FGFR1-rearranged myeloid/lymphoid neoplasms | 13.5 mg once daily continuously |
For the cholangiocarcinoma indication, treatment is administered in repeated 21-day cycles.
For the FGFR1-rearranged indication, treatment follows a continuous daily schedule.
Patients must use the schedule prescribed for their specific condition.
Administration Instructions
Pemigatinib is taken orally.
General administration instructions include:
- Take the medicine exactly as prescribed.
- Swallow the tablet whole.
- Do not crush, chew, split or dissolve the tablet.
- Take it with or without food.
- Follow the prescribed treatment calendar.
- Do not take an additional dose after vomiting.
- Follow the specific missed-dose instructions.
Missed Dose Instructions
Under U.S. reference-product instructions, if a dose is missed and the next scheduled dose is at least four hours away, the missed dose may be taken.
If the next scheduled dose is less than four hours away, the missed dose should be skipped.
The patient should then continue with the next scheduled dose.
An additional dose should not be taken to compensate for a missed dose.
Dose Modifications
Dose interruption, reduction or discontinuation may be necessary when clinically important adverse reactions occur.
The reference-product dose levels used for appropriate modifications include:
- 13.5 mg as the usual starting dose.
- 9 mg as the first reduced dose level.
- 4.5 mg as the second reduced dose level.
The correct modification depends on the adverse reaction, its severity and the patient’s clinical circumstances.
Renal and Hepatic Impairment
Patients with severe renal impairment or severe hepatic impairment may require a lower starting dose under U.S. reference-product prescribing information.
The labeled reduced starting dose for these circumstances is 9 mg once daily, using the appropriate schedule for the indication.
Kidney and liver function should be assessed by the treating healthcare professional before determining the appropriate regimen.
Contraindications
The U.S. reference-product prescribing information does not list a formal contraindication.
However, this does not mean that pemigatinib is appropriate for every patient.
The treating specialist must evaluate the indication, molecular findings, potential adverse reactions, pregnancy considerations, drug interactions and relevant medical conditions before prescribing.
Warnings and Precautions
Hyperphosphatemia
Pemigatinib can increase blood phosphate levels.
Elevated phosphate may contribute to soft-tissue mineralization and other complications.
Serum phosphate should be monitored during treatment. Depending on the results, management may include dietary changes, phosphate-lowering therapy, treatment interruption or dose modification.
Ocular Toxicity
Pemigatinib can cause ocular adverse reactions, including retinal pigment epithelial detachment.
Patients should undergo eye examinations, including OCT, before treatment and periodically during therapy.
Under U.S. reference-product labeling, examinations are recommended every two months during the first six months and every three months afterward, with additional assessments when clinically indicated.
Patients should promptly report visual symptoms.
Embryo-Fetal Toxicity
Pemigatinib may cause fetal harm.
Pregnancy status and reproductive risks should be discussed before treatment. Patients should follow the contraception recommendations in the applicable official prescribing information.
Drug Interactions
Pemigatinib is metabolized through pathways involving CYP3A.
Strong or moderate CYP3A inducers may decrease pemigatinib exposure.
Strong or moderate CYP3A inhibitors may increase pemigatinib exposure.
The reference-product prescribing information provides specific management instructions for these interactions.
Healthcare professionals should review all medicines and supplements used by the patient before treatment.
Common Adverse Reactions
Adverse reactions reported with pemigatinib vary according to the treatment indication.
In the cholangiocarcinoma population, reported adverse reactions include:
- Hyperphosphatemia.
- Alopecia.
- Diarrhea.
- Nail toxicity.
- Fatigue.
- Dysgeusia.
- Nausea.
- Constipation.
- Stomatitis.
- Dry eye.
- Dry mouth.
- Decreased appetite.
- Vomiting.
- Arthralgia.
- Abdominal pain.
- Hypophosphatemia.
- Back pain.
- Dry skin.
In the FGFR1-rearranged myeloid/lymphoid neoplasm population, reported adverse reactions include hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash and other reactions.
The frequency and severity of adverse reactions may differ between patients.
Serious Adverse Reactions
Important safety concerns include ocular toxicity and clinically significant hyperphosphatemia.
Patients should receive appropriate medical assessment for serious or persistent symptoms.
Visual changes require prompt evaluation because of the potential for retinal complications.
The treating specialist determines whether treatment should be interrupted, reduced or discontinued.
Monitoring Requirements
Monitoring during pemigatinib treatment may include:
- Serum phosphate testing.
- Kidney function.
- Liver function.
- Eye examinations and OCT.
- Assessment of visual symptoms.
- Evaluation of skin and nail changes.
- Review of gastrointestinal symptoms.
- Medication interaction assessment.
- General clinical evaluation.
The frequency of monitoring should follow the applicable prescribing information and the patient’s clinical circumstances.
Pregnancy and Lactation
Pemigatinib may cause fetal harm.
Patients who are pregnant, planning pregnancy or breastfeeding should discuss treatment risks with their healthcare professional.
The U.S. reference-product labeling provides specific contraception recommendations for females of reproductive potential during treatment and for one week after the final dose.
The potential for adverse effects on a breastfed infant should also be considered when making treatment decisions.
Storage and Handling
Store the actual medicine according to the instructions provided with its packaging and official product information.
Keep the medicine away from children and avoid using tablets that are expired, damaged or of uncertain origin.
Product-specific storage conditions should not be assumed without checking the supplied documentation.
Important Product Verification Statement
The prescribing information summarized on this page relates to pemigatinib and its established U.S. reference product.
It does not independently establish the manufacturer, regulatory authorization, packaging or approved labeling of Pemitinib 13.5 mg.
Patients and healthcare professionals should verify the specific product before use and follow its applicable official prescribing information.
Final Prescribing Reminder
Pemigatinib is a prescription targeted anticancer medicine requiring specialist supervision.
Treatment selection must be based on the appropriate cancer diagnosis, molecular testing and clinical assessment.
The treating healthcare professional is responsible for determining the correct dose, schedule, monitoring plan and management of adverse reactions.